Special Issue

Development of Antibacterial Drugs to Combat Drug-Resistant Bacteria

Message from the Guest Editor

Antimicrobial resistance is responsible for more than 35,000 deaths per year in the EU/EEA and imposes significant costs, particularly on healthcare systems. Overall, recent data suggest a significant upward trend in infections and associated deaths in almost all combinations of 'antibiotic resistance', particularly in healthcare settings. The consequence of the use of antibiotics is not only the selection of antibiotic-resistant microorganisms, but also a negative impact on the human body as a whole in the form of various side effects. Since the constant growth of the antibiotic resistance of microorganisms is becoming a global problem, the development of new therapeutic solutions, including alternatives to antimicrobial drugs, or the improvement of existing ones is urgently needed. What are the best next steps? Are there promising clinical trials that keep in mind the serious expectation that antimicrobial resistance (AMR) will kill up to 10 million people a year by 2050? Sharing your research and your thoughts can solve this major healthcare issue.

Guest Editor

Dr. Adriána Liptáková

Institute of Microbiology, Faculty of Medicine, Comenius University, University Hospital Bratislava, 81108 Bratislava, Slovakia

Deadline for manuscript submissions

closed (30 April 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/206445

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

